An estimated 20 to 30 percent of patients with inflammatory bowel disease (IBD) who are otherwise in remission continue to experience bothersome symptoms like abdominal pain, bloating, and altered bowel habits that closely resemble irritable bowel syndrome (IBS). This overlap has long confused both patients and clinicians, but a new international consensus statement is bringing clarity to a persistent clinical challenge.

What's the Difference Between IBD Remission and IBS-Like Symptoms?

IBD, which includes Crohn's disease and ulcerative colitis, is defined by chronic inflammation of the gastrointestinal tract. When patients achieve remission, standard markers of disease control typically normalize: endoscopic findings show healing, blood and stool inflammatory markers return to normal ranges, and symptoms resolve. However, clinicians have long observed that some patients continue reporting bowel symptoms even after inflammatory activity has genuinely quieted down.

The challenge lies in distinguishing these functional symptoms from a genuine disease flare. Both can present in overlapping ways, and mismanagement in either direction carries real consequences. Attributing ongoing symptoms to active disease when inflammation is truly controlled risks unnecessary escalation of immunosuppressive or biologic therapy, treatments targeting specific parts of the immune system. Conversely, dismissing symptoms as purely functional risks missing a genuine flare that requires treatment.

An international panel of thirteen gastroenterology experts developed the consensus statement to address this diagnostic gray zone. The statement formalizes expert agreement on how to recognize, characterize, and distinguish IBS-like symptoms from ongoing inflammatory activity, providing clinicians with a shared reference point when objective disease control and subjective symptom burden diverge.

Why Do Some IBD Patients Experience IBS-Like Symptoms in Remission?

The reasons behind this phenomenon are not fully explained in the consensus statement itself, but the clinical reality is clear: standard markers of IBD remission do not always correspond with a patient's actual symptomatic experience. This disconnect highlights an important gap between what laboratory tests and endoscopy show and what patients feel day to day.

For patients, having a recognized clinical framework for these symptoms may help validate an experience that has historically been difficult to categorize within routine follow-up appointments. Many patients have felt caught between two diagnoses, unsure whether their ongoing discomfort represents active disease or something else entirely.

How Should Clinicians Approach This Overlap?

The consensus statement aims to provide gastroenterologists, IBD nurses, and dietitians with practical guidance when symptoms and objective disease markers do not align. While the full detail of the panel's specific recommendations was not disclosed in available reporting, the statement's existence signals a shift toward recognizing IBS-like symptoms in remission as a legitimate clinical entity worthy of structured assessment rather than dismissal.

This distinction has direct implications for patient care. A clinician who understands the overlap can avoid unnecessary treatment escalation while still taking symptoms seriously. For patients, it means their experience is increasingly recognized as a real clinical phenomenon rather than being told their symptoms are "all in their head" or simply a sign of inadequately controlled disease.

Steps for Managing IBD and Recognizing Symptom Changes

• Maintain consistent medication routines: Even when disease is in remission, missing doses or irregular medication timing can disrupt the stability that keeps symptoms manageable. Phone reminders, pill organizers, and backup supplies kept separately from your main stash help prevent missed doses.
• Track sleep and stress patterns: Irregular sleep and high stress do not directly cause IBD, but research suggests they may influence symptom perception and the timing of flares through the nervous system's communication with the gut and immune activity. Building simple sleep and workload routines can help buffer this pressure during exams or busy periods.
• Monitor dietary consistency: Sudden, large shifts in fiber intake, alcohol, or very spicy or fatty foods can trigger discomfort even when underlying inflammation is stable. Keeping a few reliable, well-tolerated meals in rotation reduces trial-and-error stress and helps identify true triggers.
• Distinguish between symptom types: Not every stomach ache or bowel change during a stressful period means the disease is flaring. Diet changes, bugs going around, and simple anxiety can all mimic IBD symptoms. If symptoms persist, worsen, or include blood, weight loss, or fever, contact your IBD team rather than assuming it will settle on its own.
• Register with local healthcare support: If you are transitioning to a new location, register with a GP surgery and gastroenterology team near your new address. Ask your current IBD team whether care can transfer or whether they can prescribe remotely for a period. Many UK IBD teams can arrange a shared care letter summarizing your history, current treatment, and allergies.

What Does This Mean for Patients Living With IBD?

The new consensus statement represents a validation of patient experience. For years, people with IBD in remission who continued to experience symptoms often felt unheard or misunderstood. Clinicians might attribute lingering symptoms to anxiety or dietary indiscretion rather than recognizing them as a distinct clinical phenomenon. Now, with formalized expert guidance, these symptoms have a name and a framework for assessment.

For patients managing IBD away from home, such as students starting university, the principles remain consistent: maintaining medication routines, managing stress, and staying connected to a responsive medical team matter more than any single dietary rule. The core goal is building a stable foundation that allows you to manage your condition rather than having unpredictable symptoms manage you.

The consensus statement also underscores an important message: if you are living with IBD and experiencing ongoing symptoms despite being told your disease is in remission, those symptoms deserve attention and assessment. You are not alone, and your experience is increasingly recognized as a legitimate clinical concern worthy of expert evaluation and individualized management.